Tonix Pharmaceuticals Holding Corp. develops and commercializes biotechnology products for central nervous system disorders, immunology, infectious diseases and rare diseases. Company news centers on TONMYA, an FDA-approved cyclobenzaprine HCl sublingual tablet for fibromyalgia in adults, along with marketed acute migraine products Zembrace SymTouch and Tosymra.
Recurring updates also cover Tonix’s development pipeline, including TNX-4800, a long-acting anti-Borrelia OspA human monoclonal antibody for Lyme disease prophylaxis; TNX-1900 intranasal potentiated oxytocin for craniofacial pain conditions; TNX-1700 and TNX-4700 immuno-oncology programs; TNX-801 vaccine research; and TNX-1500 for prevention of kidney transplant rejection. Other company developments include scientific presentations, clinical and preclinical data, commercial access arrangements, operating results, capital-structure disclosures and governance matters.
Tonix Pharmaceuticals (Nasdaq: TNXP) announced the presentation of two pharmacokinetic studies at the ASCP 2020 Annual Meeting held online on May 29-30. One study focused on TNX-102 SL, a potential treatment for fibromyalgia and PTSD, showing dose-proportional absorption without food effects. The other study evaluated TNX-601 CR, a once-daily formulation for major depressive disorder and PTSD, demonstrating suitability for once-daily dosing and good tolerability. The company continues to advance its drug candidates, with key trial results expected soon.